Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763786 | 0.88 | HDAC3 (0.74) | HDAC3NCOR2NPC1RAB9AHDAC1 | |
| SCHEMBL9191952 | 0.87 | HDAC3 (0.71) | HDAC3NCOR2NPC1RAB9AHDAC1 | |
| SCHEMBL1374654 | 0.84 | HDAC3 (0.68) | HDAC3NCOR2NPC1RAB9AHDAC1 | |
| SCHEMBL1377409 | 0.84 | HDAC3 (0.68) | HDAC3NCOR2NPC1RAB9AHDAC1 | |
| SCHEMBL8163537 | 0.82 | HDAC3 (0.67) | HDAC3NCOR2HDAC1HDAC2HDAC8 | |
| SCHEMBL3057437 | 0.82 | HDAC3 (0.71) | HDAC3NCOR2NPC1RAB9AHDAC1 | |
| SCHEMBL8081432 | 0.82 | HDAC3 (0.71) | HDAC3NCOR2NPC1RAB9AHDAC1 | |
| SCHEMBL449555 | 0.82 | HDAC3 (0.71) | HDAC3NCOR2NPC1RAB9AHDAC1 | |
| SCHEMBL5794325 | 0.82 | HDAC3 (0.67) | HDAC3NCOR2NPC1RAB9AHDAC1 | |
| SCHEMBL4230565 | 0.82 | HDAC3 (0.71) | HDAC3NCOR2NPC1RAB9AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-RE38506-E1 | HYDROXYLAMIDE AND BENZYLAMIDE FUNCTIONALIZED; ANTIPROLIFERA-TIVE AGENTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-04-20 | — | — | US | disclosed |
| US-6087367-A | INHIBITING PROLIFERATION OF TUMOR CELLS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0642509-B1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF | SLOAN KETTERING INST CANCER (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5932616-A | Potent inducers of terminal differentiation and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0760657-A4 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF | SLOAN KETTERING INST CANCER (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5700811-A | ADMINISTERING COMPOUNDS CONTAINING HYDROXAMIC ACID GROUPS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0760657-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995031977-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-11-30 | — | — | WO | disclosed |
| EP-0642509-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0642509-A4 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF. | SLOAN KETTERING INST CANCER (US) | 1995-01-31 | — | — | EP | disclosed |
| US-5369108-A | Antitumor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1994-11-29 | — | — | US | disclosed |
| WO-1993007148-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885NCOR2 315/4885NPC1 2251/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885NCOR2 315/4885NPC1 2251/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885NCOR2 315/4885NPC1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.